web analytics

Nanotraps for the containment and clearance of SARS-CoV-2

Published:
Lead Inventor: Jun Huang
Print or Save to PDF

SUMMARY

  • Inventors devised a nanomedicine termed “Nanotraps” that can completely capture and eliminate SARS-CoV-2 by triggering macrophages to engulf and clear the virus without becoming infected.
  • Ex vivo lung perfusion system. Zero toxicity was found in mice as evidenced by histological analysis of heart, liver, spleen, lung, and kidney, as well as blood chemistry and blood cell counts.
  • The Nanotraps have the potential to be formulated into a nasal spray or inhaler for easy administration and direct delivery to the respiratory system, as an oral or ocular liquid, or subcutaneous, intramuscular, or intravenous injection to target different sites of SARS-CoV-2 exposure, thus offering flexibility in administration and treatment.

 

FIGURE

A) Scanning electron microscopy images of SARS-CoV-2 pseudovirus (cyan) captured by Nanotraps (orange). Scale bars: 300 nm. B) Neutralizing assay of pseudotyped SARS-CoV-2 infection of HEK293T-ACE2 cells comparing Nanotraps to soluble ACE2. C) Evaluation of pseudotyped SARS-CoV-2 infection of ex vivo lung perfusion system with live human lungs. D) Neutralizing assay of authentic SARS-CoV-2 infection of Vero E6 cells comparing Nanotraps to neutralizing antibody.

 

ADVANTAGES

ADVANTAGES

  • 10 times more effective than soluble ACE2 or neutralizing antibody counterparts
  • Stable after lyophilization at -20C for six months
  • Could be aerosolized for drug delivery via nasal spray

APPLICATIONS

  • Therapeutics
  • Preliminary toxicology studies